维普期刊资源整合服务平台（V6.5）

23篇 您的检索式：作者名="HENDLISZ A"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/ phosphorylated epidermal growth factor receptor in metastatic coloreetal cancer 显示文摘	Personeni N Hendlisz A Gallez J	2005	Semin Oncol2005，32，9：	1
2	Treatment of colorectal liver metastases: a review显示文摘	Van den Eynde M Hendlisz A	2009	Rev Recent Clin Trials2009，4，1：	1
3	Treatment of colorectal livermetastases: a review显示文摘	Van den Eynde M Hendlisz A	2009	Rev Recent Clin Trials2009，4，1：	1
4	Modulation and prognostic value of epidermal growth factor receptor (EGFR) expression in circulating tumor cells (CTCs) during chemotherapy (CT) in patients with metastatic colorectal cancer 显示文摘	Hendlisz A Marechal R Durbecq V	2008	J Clin Oncol2008，26，：	1
5	Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours显示文摘	AWADA A HENDLISZ A GIL T	2005	Brit J Can2005，92，10：	1
6	Modulation and prognostic value of epidermal growth factor receptor(EGFR)expression in circulating tumor cells(CTC)during chemotherapy(CT)in patients with metastatic colorectal cancer显示文摘	HENDLISZ A MARECHAL R DURBECQ V	2008	J Clin Oncol2008，26，15：	1
7	Phase Ⅰ safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumors 显示文摘	Awada A Hendlisz A Gil T	2005	Br J Cancer2005，92，10：	1
8	New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspe显示文摘	Awada A Mano M Hendlisz A	2004	Expert Rev Anticancer Ther2004，4，1：	1
9	New anticancer agents and therapeutic strategies in development for solid cancers: A clinical perspective 显示文摘	Awada A Mano M Hendlisz A	2004	Expert Rev Anticaneer Ther2004，4，1：	1
10	查看详情显示文摘	Deleporte A Flamen P Hendlisz A		0，，：	1
11	Phase I safety and pharmacokineties of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours显示文摘	Awada A Hendlisz A Gil T	2005	Br J Cancer2005，92，10：	1
12	Phase Ⅰ safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced,refractory solid tumours显示文摘	AWADA A HENDLISZ A GIL T	2005	Br J Cancer2005，92，10：	1
13	Treatment of colorectal liver metastases : a review显示文摘	Van den Eynde M Hendlisz A	2009	Rev Recent Clin Trials2009，4，1：	1
14	Treatment of colorectal liver metastases: 1 review显示文摘	Vanden Eynde M Hendlisz A	2009	Rev Recent Clin Trials2009，4，1：	1
15	Treatment of colorectal liver metasta- ses : a revlew显示文摘	Van den Eynde M Hendlisz A		Rev Recent Clin Trials0，4，1：	1
16	Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer显示文摘	Personeni N Hendlisz A Gallez J	2005	Semin Oncol2005，32，9：	1
17	Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer显示文摘	Personeni N Hendlisz A Gallez J	2005	Semin Oncol2005，32，6：	1
18	Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumors显示文摘	AWADA A HENDLISZ A GIL T	2005	Br J Cancer2005，92，10：	1
19	Treatment of coloretal liver metastases: a review显示文摘	Vanden Eynde M Hendlisz A	2009	Rev Recent Clin Trials2009，4，1：	1
20	Phase Ⅰ safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advangced,refractory solid tumors显示文摘	Awada A HendLisz A Gil T	2005	Br J Cancer2005，92，10：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示